Purpose: The complement system is activated via 3 different pathways; the lectin pathway (LP), classical pathway (CP), and alternative pathway. To investigate the possible roles for the LP or CP in the development of neovascular age-related macular degeneration (nAMD), we compared aqueous humor levels of complement proteins of the LP and CP between eyes with nAMD and those with cataract as controls. Methods: Seventeen eyes from 17 patients with treatment-naïve nAMD and 9 eyes from 9 patients with cataract were studied. Aqueous humor samples were collected before intravitreal aflibercept or ranibizumab injection for the nAMD patients and before cataract surgery for the cataract patients. Aqueous humor levels of complement C4 of the LP and CP, complement C3 of all 3 complement pathways, and mannose-binding lectin-associated serine protease (MASP)-2 of the LP were measured by enzyme-linked immunosorbent assay. Aqueous humor levels of C4a and C3a, the activation products of C4 and C3, respectively, were measured by a bead-based immunoassay. The ratios of C4a to C4 and C3a to C3, representing the degree of C4 and C3 activation, respectively, were calculated in individual patients. Results: The aqueous humor levels of C4, C3, and MASP-2 were significantly lower in the nAMD eyes compared to the controls (p = 0.008, p = 0.011, and p = 0.018, respectively). In contrast, the aqueous humor levels of C4a and C3a, as well as the C4a/C4 and C3a/C3 ratios, were significantly higher in the nAMD eyes compared to the controls (p = 0.039, p = 0.003, p < 0.001, and p < 0.001, respectively). Conclusions: This study provides evidence for significant intraocular activation of either or both of the LP and CP in nAMD eyes that might be involved in the development of nAMD. The significantly lower levels of MASP-2 in the aqueous humor of the nAMD eyes were likely due to MASP-2 consumption by activation of the LP.

1.
Congdon
N
,
O’Colmain
B
,
Klaver
CC
,
Klein
R
,
Muñoz
B
,
Friedman
DS
, et al;
Eye Diseases Prevalence Research Group
.
Causes and prevalence of visual impairment among adults in the United States
.
Arch Ophthalmol
.
2004
Apr
;
122
(
4
):
477
85
.
[PubMed]
0003-9950
2.
Wong
WL
,
Su
X
,
Li
X
,
Cheung
CM
,
Klein
R
,
Cheng
CY
, et al
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
.
Lancet Glob Health
.
2014
Feb
;
2
(
2
):
e106
16
.
[PubMed]
2214-109X
3.
Oshima
Y
,
Ishibashi
T
,
Murata
T
,
Tahara
Y
,
Kiyohara
Y
,
Kubota
T
.
Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study
.
Br J Ophthalmol
.
2001
Oct
;
85
(
10
):
1153
7
.
[PubMed]
0007-1161
4.
Hageman
GS
,
Luthert
PJ
,
Victor Chong
NH
,
Johnson
LV
,
Anderson
DH
,
Mullins
RF
.
An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration
.
Prog Retin Eye Res
.
2001
Nov
;
20
(
6
):
705
32
.
[PubMed]
1350-9462
5.
Ambati
J
,
Atkinson
JP
,
Gelfand
BD
.
Immunology of age-related macular degeneration
.
Nat Rev Immunol
.
2013
Jun
;
13
(
6
):
438
51
.
[PubMed]
1474-1733
6.
Ricklin
D
,
Hajishengallis
G
,
Yang
K
,
Lambris
JD
.
Complement: a key system for immune surveillance and homeostasis
.
Nat Immunol
.
2010
Sep
;
11
(
9
):
785
97
.
[PubMed]
1529-2908
7.
Yaseen
S
,
Demopulos
G
,
Dudler
T
,
Yabuki
M
,
Wood
CL
,
Cummings
WJ
, et al
Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2
.
FASEB J
.
2017
May
;
31
(
5
):
2210
9
.
[PubMed]
0892-6638
8.
Liszewski
MK
,
Java
A
,
Schramm
EC
,
Atkinson
JP
.
Complement dysregulation and disease: insights from contemporary genetics
.
Annu Rev Pathol
.
2017
Jan
;
12
(
1
):
25
52
.
[PubMed]
1553-4006
9.
Klein
RJ
,
Zeiss
C
,
Chew
EY
,
Tsai
JY
,
Sackler
RS
,
Haynes
C
, et al
Complement factor H polymorphism in age-related macular degeneration
.
Science
.
2005
Apr
;
308
(
5720
):
385
9
.
[PubMed]
0036-8075
10.
Haines
JL
,
Hauser
MA
,
Schmidt
S
,
Scott
WK
,
Olson
LM
,
Gallins
P
, et al
Complement factor H variant increases the risk of age-related macular degeneration
.
Science
.
2005
Apr
;
308
(
5720
):
419
21
.
[PubMed]
0036-8075
11.
Edwards
AO
,
Ritter
R
 3rd
,
Abel
KJ
,
Manning
A
,
Panhuysen
C
,
Farrer
LA
.
Complement factor H polymorphism and age-related macular degeneration
.
Science
.
2005
Apr
;
308
(
5720
):
421
4
.
[PubMed]
0036-8075
12.
Schick
T
,
Steinhauer
M
,
Aslanidis
A
,
Altay
L
,
Karlstetter
M
,
Langmann
T
, et al
Local complement activation in aqueous humor in patients with age-related macular degeneration
.
Eye (Lond)
.
2017
May
;
31
(
5
):
810
3
.
[PubMed]
0950-222X
13.
Yang
Y
,
Chung
EK
,
Zhou
B
,
Blanchong
CA
,
Yu
CY
,
Füst
G
, et al
Diversity in intrinsic strengths of the human complement system: serum C4 protein concentrations correlate with C4 gene size and polygenic variations, hemolytic activities, and body mass index
.
J Immunol
.
2003
Sep
;
171
(
5
):
2734
45
.
[PubMed]
0022-1767
14.
Thiel
S
,
Steffensen
R
,
Christensen
IJ
,
Ip
WK
,
Lau
YL
,
Reason
IJ
, et al
Deficiency of mannan-binding lectin associated serine protease-2 due to missense polymorphisms
.
Genes Immun
.
2007
Mar
;
8
(
2
):
154
63
.
[PubMed]
1466-4879
15.
Sallenbach
S
,
Thiel
S
,
Aebi
C
,
Otth
M
,
Bigler
S
,
Jensenius
JC
, et al
Serum concentrations of lectin-pathway components in healthy neonates, children and adults: mannan-binding lectin (MBL), M-, L-, and H-ficolin, and MBL-associated serine protease-2 (MASP-2)
.
Pediatr Allergy Immunol
.
2011
Jun
;
22
(
4
):
424
30
.
[PubMed]
0905-6157
16.
Zhang
M
,
Hou
YJ
,
Cavusoglu
E
,
Lee
DC
,
Steffensen
R
,
Yang
L
, et al
MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans
.
Int J Cardiol
.
2013
Jun
;
166
(
2
):
499
504
.
[PubMed]
0167-5273
17.
Mondino
BJ
,
Sumner
H
.
Complement inhibitors in normal cornea and aqueous humor
.
Invest Ophthalmol Vis Sci
.
1984
Apr
;
25
(
4
):
483
6
.
[PubMed]
0146-0404
18.
Joseph
K
,
Kulik
L
,
Coughlin
B
,
Kunchithapautham
K
,
Bandyopadhyay
M
,
Thiel
S
, et al
Oxidative stress sensitizes retinal pigmented epithelial (RPE) cells to complement-mediated injury in a natural antibody-, lectin pathway-, and phospholipid epitope-dependent manner
.
J Biol Chem
.
2013
May
;
288
(
18
):
12753
65
.
[PubMed]
0021-9258
19.
Schumaker
VN
,
Calcott
MA
,
Spiegelberg
HL
,
Müller-Eberhard
HJ
.
Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement
.
Biochemistry
.
1976
Nov
;
15
(
23
):
5175
81
.
[PubMed]
0006-2960
20.
Wild
G
,
Watkins
J
,
Ward
AM
,
Hughes
P
,
Hume
A
,
Rowell
NR
.
C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus
.
Clin Exp Immunol
.
1990
May
;
80
(
2
):
167
70
.
[PubMed]
0009-9104
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.